Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — ZIOPHARM Oncology — Investor Presentation (March 2014)
21 slides from Alaunos Therapeutics's investor presentation, Mar 28, 2014
Slide 1: The Future of Cancer Therapy
March The Future of Cancer Therapy www.ziopharm.com Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains certain forward-looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are n
Slide 3: ZIOPHARM Today: Clinical-stage Immuno-Oncology company
Clinical-stage Immuno - Oncology company Focus on treatment through DNA expression and cell control Phase 1/2 program targeting melanoma, breast cancer and glioma Intrexon partnership enabling potential paradigm shift New INDs through 2015 exploring multigenic approach to cancer treatment ZIOPHARM T
Slide 4: Why Focus on DNA-Based Medicine?
DNA synthesis and delivery enable: creation of new therapies which target cancer cells precise control of biologic concentration and dosing better therapeutic index through controlled protein delivery and cellular targeting economically feasible approach biologic therapies and Immuno- Oncology Why F
Slide 5: Intrexon Collaboration: Leveraging Our Assets
ZIOP: translational medicine and oncology drug development XON: synthetic biology platform enabling DNA delivery and control Exclusive channel partner agreement for the treatment of all human cancer: ZIOP responsible for product development and commercialization XON responsible for manufacturing, pr
Slide 6: We Have the Tools to Treat Cancer Better
Immune Cells Non-immune Cells We Have the Tools to Treat Cancer Better Cytokines mAb scFv scFv toxin Systemic decoy Intracellular decoy Metabolic Enzyme RNA Protein Ligand DC T Cell B Cell Macrophage NK cell Treg Other immune cells Direct tumor lysis ADCC Complement cytotoxicity Innate immunity stim
Slide 7: Gene Expression RheoSwitch
Gene Expression RheoSwitch® Controlled Expression and Delivery of Therapeutic Proteins with Intrexon’s RheoSwitch®: This is the most advanced clinical method to turn genes on and off The Power of RheoSwitch® Technology High Potency Monogenic/Multigenic Dose-control Orally activated biologic on/off s
Slide 8: Ad-RTS-IL-12: Solving the Problem of Serum Concentration
Ad-RTS-IL-12: Solving the Problem of Serum Concentration rIL-12 = recombinant IL-12 hIL-12 = Ad- RTS- IL-12 *Atkins, MB et al Clin Cancer Res 1997;3:409-417 11137 ± 27 ± rIL-12* hIL-12
Slide 9: IL-12 Production is Modulated by Veledimex
OFF OFF ON IL-12 Production is Modulated by Veledimex (Activator Ligand) in HT 1080 Cells -1 Time after viral transduction (hours)
Slide 10: Oral Veledimex Tightly Controls IL-12 mRNA Expression in Tumor
OFF OFF ON Oral Veledimex Tightly and Precisely Controls the Expression of IL-12 ß mRNA in the Tumor Veledimex Dose n=7 0.1 Baseline Maximum D1-D7 7 Days Post-treatment 100 mg 160 mg
Slide 11: Cytotoxic T Cells Increase in Tumors Following Ad-RTS-IL-12
On Off Cytotoxic T Cells & Memory T Cells (TILs) Significantly Increase in Tumors Following Ad-RTS-IL-12 Treatment Images were obtained using an Aperio ScanScope XT whole-slide imager and digitized at 20x. CD8+ CD45RO+
Slide 12: Systemic Immune Activity: Patterns of Anti-Tumor Response
Systemic Immune Activity: Patterns of Anti-Tumor Response Patient# -75 -50 -25
Slide 13: Clinical Observations to Date
High expression of IL-12 mRNA in tumors, tightly controlled by veledimex dose Clinical Observations to Date We can control gene expression to achieve a desirable immune response We have seen potent systemic biologic activity and reversible toxicity Melanoma: potent biologic activity in injected and
Slide 14: Glioblastoma Multiforme: IL-12 Preclinical Activity Measuring Survival
Kaplan Meier Survival in GL261 Orthotopic Syngeneic Mouse Glioma Model Glioblastoma Multiforme: IL-12 Preclinical Activity Measuring Survival Veledimex (AL) dosing Day 4 to EOS at ~ 675 mg/m2/day in chow; DC-RTS-IL-12 or Ad-RTS-IL-12 on Day 5 100% survival observed with Ad-RTS-IL-12 + AL or DC-RTS-I
Slide 15: Significant Market Potential for Ad-RTS-IL-12
Significant Market Potential for Ad-RTS-IL-12 Melanoma 76,690 Breast Cancer 234,580 Incidence Glioma 18,000
Slide 16: A Growing Oncology Portfolio
Pre Clinical Phase 1 Phase 2 A Growing Oncology Portfolio Compound Ad-RTS-IL-12 IND Melanoma Breast GBM Cell-based programs Immuno-Oncology programs Cell signal targeting Multigenic platforms
Slide 17: DNA Combination Therapies: Potential Future INDs
Human allogeneic mesenchymal stem cells genetically modified with genes that activate the immune system to destroy cancer Multigenic therapeutic antibodies such as single chain versions of Herceptin® and Erbitux® Embedded cellular bioreactors to deliver multiple proteins systemically using RheoSwitc
Slide 18: Upcoming Clinical Milestones
Program Milestone Timing Upcoming Clinical Milestones Breast cancer Initiate Phase 2 combination study with SOC 1H 2014 - Report preliminary data 1H 2015 Report results from ongoing Phase 2 study Melanoma Initiate Phase 2 combination study with SOC 1H 2014 - Report preliminary data YE 2014 Report re
Slide 19: Financial Highlights
Approx. 100 million shares outstanding Approx. $68 million in cash and investments No debt Development partner/top shareholder: Intrexon Corp. (NYSE: XON) Financial Highlights
Slide 20: Why Invest in ZIOPHARM?
We understand the biologic basis of cancer- and how to engineer new products We have the ability to deliver DNA and stimulate a controlled therapeutic immune response Clinical testing is validating our vision Intrexon partnership is enabling expansion of our pipeline Big pharma is very interested in
Slide 21: The Future of Cancer Therapy
NASDAQ: ZIOP The Future of Cancer Therapy www.ziopharm.com
ZIOPHARM Oncology — Investor Presentation (March 2014) on 6ix